223 related articles for article (PubMed ID: 24752333)
1. Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles.
Munster M; Fremder E; Miller V; Ben-Tsedek N; Davidi S; Scherer SJ; Shaked Y
PLoS One; 2014; 9(4):e95983. PubMed ID: 24752333
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.
Fremder E; Munster M; Aharon A; Miller V; Gingis-Velitski S; Voloshin T; Alishekevitz D; Bril R; Scherer SJ; Loven D; Brenner B; Shaked Y
Int J Cancer; 2014 Jul; 135(2):270-81. PubMed ID: 24347266
[TBL] [Abstract][Full Text] [Related]
3. Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60.
Yang J; Wang Q; Qiao C; Lin Z; Li X; Huang Y; Zhou T; Li Y; Shen B; Lv M; Feng J
Cell Mol Immunol; 2014 May; 11(3):285-93. PubMed ID: 24608894
[TBL] [Abstract][Full Text] [Related]
4. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
8. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies.
Boer JC; Walenkamp AM; den Dunnen WF
Crit Rev Oncol Hematol; 2014 Oct; 92(1):38-48. PubMed ID: 24933160
[TBL] [Abstract][Full Text] [Related]
10. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.
Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH
J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of radiation response with bevacizumab.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
J Exp Clin Cancer Res; 2012 Apr; 31(1):37. PubMed ID: 22538017
[TBL] [Abstract][Full Text] [Related]
12. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
Finn RS; Bentley G; Britten CD; Amado R; Busuttil RW
Liver Int; 2009 Feb; 29(2):284-90. PubMed ID: 18482274
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
15. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.
Banerjee A; Wu ZS; Qian PX; Kang J; Liu DX; Zhu T; Lobie PE
PLoS One; 2012; 7(11):e50098. PubMed ID: 23185544
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Activity of Acer tegmentosum Maxim Water Extract in Vitro and in Vivo.
Kim EC; Kim SH; Piao SJ; Kim TJ; Bae K; Kim HS; Hong SS; Lee BI; Nam M
J Korean Med Sci; 2015 Jul; 30(7):979-87. PubMed ID: 26130964
[TBL] [Abstract][Full Text] [Related]
18. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.
Bausch D; Pausch T; Krauss T; Hopt UT; Fernandez-del-Castillo C; Warshaw AL; Thayer SP; Keck T
Angiogenesis; 2011 Sep; 14(3):235-43. PubMed ID: 21442180
[TBL] [Abstract][Full Text] [Related]
20. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing.
Feng W; Madajka M; Kerr BA; Mahabeleshwar GH; Whiteheart SW; Byzova TV
Blood; 2011 Apr; 117(14):3893-902. PubMed ID: 21224474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
